EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%
| dc.contributor.author | Gogishvili, M. | |
| dc.contributor.author | Sezer, A. | |
| dc.contributor.author | Kilickap, S. | |
| dc.contributor.author | Gumus, M. | |
| dc.contributor.author | Bondarenko, I. | |
| dc.contributor.author | ÖZGÜROĞLU, Mustafa | |
| dc.contributor.author | TÜRK, HACI MEHMET | |
| dc.contributor.author | Cicin, I. | |
| dc.contributor.author | Bentsion, D. | |
| dc.contributor.author | Gladkov, O. | |
| dc.contributor.author | Clingan, P. | |
| dc.contributor.author | Sriuranpong, V. | |
| dc.contributor.author | Rizvi, N. | |
| dc.contributor.author | Li, S. | |
| dc.contributor.author | Lee, S. | |
| dc.contributor.author | Gullo, G. | |
| dc.contributor.author | Lowy, I. | |
| dc.contributor.author | Rietschel, P. | |
| dc.date.accessioned | 2021-03-03T07:35:57Z | |
| dc.date.available | 2021-03-03T07:35:57Z | |
| dc.identifier.citation | Sezer A., Kilickap S., Gumus M., Bondarenko I., ÖZGÜROĞLU M., Gogishvili M., TÜRK H. M. , Cicin I., Bentsion D., Gladkov O., et al., "EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%", ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31 | |
| dc.identifier.other | av_12d0d972-4206-4780-9835-980728387c43 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/18097 | |
| dc.identifier.uri | https://doi.org/10.1016/j.annonc.2020.08.2285 | |
| dc.language.iso | eng | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | ONKOLOJİ | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Onkoloji | |
| dc.title | EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50% | |
| dc.type | Bildiri | |
| dc.contributor.department | Başkent Üniversitesi , , | |
| dc.identifier.volume | 31 | |
| dc.contributor.firstauthorID | 2286909 |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
This item appears in the following Collection(s)
-
Bildiri [64839]